Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients
Influence of Liraglutide on Diastolic Cardiac Function and Myocardial Perfusion as Determined by Magnetic Resonance Imaging in Patients With Type 2 Diabetes: a Double-blind Randomized Parallel-group Trial
Sponsor: Novo Nordisk A/S
Listed as NCT02655770, this PHASE4 trial focuses on Cardiac MRI and Diabetes Mellitus Type 2 and remains completed. Sponsored by Novo Nordisk A/S, it has been updated 9 times since 2016, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Oct 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Oct 2018 — Oct 2019 [monthly]
Recruiting PHASE4
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
Feb 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
- Rigshospitalet, Denmark
- Slagelse Hospital
For direct contact, visit the study record on ClinicalTrials.gov .